法司努單抗
化合物
法司努單抗（INN：Fasinumab）是一種人單克隆抗體，設計用於治療急性坐骨神經痛。[1][2]該藥物由梯瓦製藥工業有限公司和再生元製藥公司合作開發。目前正處於III期試驗（NCT03245008、NCT02683239和NCT03161093）。[3]
| 單克隆抗體 | |
|---|---|
| 種類 | ? |
| 目標 | HNGF |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1190239-42-9 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6406H9896N1700O2026S46 |
| 摩爾質量 | 144,618.27 g·mol−1 |
參考資料
編輯- ^ Fasinumab (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. [2023-12-06]. （原始內容存檔 (PDF)於2020-04-14）.
- ^ Tiseo PJ, Ren H, Mellis S. Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. Journal of Pain Research. 2014, 7: 523–530. PMC 4155988
. PMID 25210473. doi:10.2147/JPR.S65974 .
- ^ Oo WM, Hunter DJ. Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review. BioDrugs. November 2021, 35 (6): 611–641. PMID 34807432. S2CID 244509341. doi:10.1007/s40259-021-00504-8.
